Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers
| Status: | Recruiting |
|---|---|
| Conditions: | Breast Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/20/2019 |
| Start Date: | June 14, 2016 |
| End Date: | October 30, 2020 |
| Contact: | Novartis Pharmaceuticals |
| Email: | Novartis.email@novartis.com |
| Phone: | 1-888-669-6682 |
A Phase I/Ib, Open Label Study of LSZ102 Single Agent and LSZ102 in Combination With Either LEE011 (LSZ102 + LEE011) or BYL719 (LSZ102 + BYL719) in Patients With Advanced or Metastatic ER+ Breast Cancer Who Have Progressed After Endocrine Therapy
To characterize the safety and tolerability, identify recommended doses and regimens for
future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of
LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients
with locally advanced or metastatic ER+ breast cancer who have progressed after endocrine
therapy.
future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of
LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients
with locally advanced or metastatic ER+ breast cancer who have progressed after endocrine
therapy.
Inclusion Criteria:
- Written informed consent must be obtained prior to any procedures
- Histologically and/or cytologically confirmed diagnosis of ER+/HER2- breast cancer
- Advanced or metastatic breast cancer
- Must be able to swallow tablets and capsules
Exclusion Criteria:
- Symptomatic CNS metastases
- Patients whose laboratory values do not meet protocol criteria
- Clinically significant cardiac disease
- Impaired gastrointestinal function (GI) or GI disease that may significantly alter the
absorption of oral medications
Other protocol defined inclusion/exclusion criteria may apply.
We found this trial at
5
sites
Click here to add this to my saved trials
Boston, Massachusetts 02114
Principal Investigator: Dejan Juric, MD
Phone: 617-726-6500
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
230 Park Avenue, 21st Floor
New York, New York 10169
New York, New York 10169
1-888-669-6682)
Principal Investigator: Komal Jhaveri
Phone: 646-422-4394
Novartis Novartis, which was created in 1996 by the merger of the Swiss companies Ciba-Geigy...
Click here to add this to my saved trials